SEC
|
Combs Andrew
|
Chief Chemistry Officer
|
|
+100K
|
$0.69
|
+$69.00K
|
|
SEC
|
Vaddi Krishna
|
CEO
|
|
+675K
|
$0.69
|
+$465.75K
|
|
SEC
|
Vaddi Krishna
|
CEO
|
|
+20K
|
$0.73
|
+$14.90K
|
|
SEC
|
Vaddi Krishna
|
CEO
|
|
+39K
|
$0.75
|
+$29.33K
|
|
SEC
|
Vaddi Krishna
|
CEO
|
|
+98K
|
$0.71
|
+$69.23K
|
|
SEC
|
Vaddi Krishna
|
CEO
|
|
+5K
|
$1.21
|
+$6.05K
|
|
SEC
|
Vaddi Krishna
|
CEO
|
|
+10K
|
$1.20
|
+$12.00K
|
|
SEC
|
Combs Andrew
|
Chief Chemistry Officer
|
|
+63K
|
$1.36
|
+$85.78K
|
|
SEC
|
Lim Bryant David
|
CLO, Interim CFO, Corp Sec.
|
|
+25K
|
$0.91
|
+$22.75K
|
|
SEC
|
Vaddi Krishna
|
CEO
|
|
+107K
|
$0.93
|
+$99.41K
|
|
SEC
|
Vaddi Krishna
|
CEO
|
|
+1.9K
|
$5.15
|
+$9.79K
|
|
SEC
|
Lim Bryant David
|
Chief Legal Officer, Corp Sec.
|
|
+2.4K
|
$5.39
|
+$12.94K
|
|
SEC
|
Chardonnet Laurent
|
Chief Financial Officer
|
|
+5K
|
$5.50
|
+$27.50K
|
|
SEC
|
Vaddi Krishna
|
CEO
|
|
+12K
|
$5.63
|
+$66.75K
|
|
SEC
|
Bonita David P
|
N/A
|
|
+870K
|
$5.75
|
+$5.00M
|
|
SEC
|
ORBIMED CAPITAL LLC
|
N/A
|
|
+870K
|
$5.75
|
+$5.00M
|
|
SEC
|
Huang Jane
|
President, CMO
|
|
-13K
|
$6.12
|
-$81.27K
|
|
SEC
|
Vaddi Krishna
|
CEO
|
|
+19K
|
$5.13
|
+$98.43K
|
|
SEC
|
Chardonnet Laurent
|
Chief Financial Officer
|
|
+10K
|
$4.76
|
+$47.60K
|
|
SEC
|
Chardonnet Laurent
|
Chief Financial Officer
|
|
+10K
|
$4.23
|
+$42.30K
|
|
SEC
|
Combs Andrew
|
EVP, Head of Chemistry
|
|
+36K
|
$1.89
|
+$68.16K
|
|
SEC
|
Chardonnet Laurent
|
Chief Financial Officer
|
|
+6.5K
|
$7.51
|
+$48.82K
|
|
SEC
|
Combs Andrew
|
EVP, Head of Chemistry
|
|
+8K
|
$11.86
|
+$94.88K
|
|
SEC
|
Chardonnet Laurent
|
Chief Financial Officer
|
|
+5K
|
$12.28
|
+$61.40K
|
|
SEC
|
Vaddi Krishna
|
President, CEO
|
|
+8K
|
$12.13
|
+$97.04K
|
|
SEC
|
Pierce Christopher
|
EVP and Chief of Business Oper
|
|
-17K
|
$41.68
|
-$708.56K
|
|
SEC
|
Piper Brian
|
Chief Financial Officer
|
|
-8.3K
|
$33.34
|
-$277.82K
|
|
SEC
|
Scherle Peggy
|
Chief Scientific Officer
|
|
-20K
|
$35.47
|
-$709.40K
|
|
SEC
|
Piper Brian
|
Chief Financial Officer
|
|
-8.3K
|
$34.27
|
-$285.57K
|
|
SEC
|
Mauro David J
|
Chief Medical Officer
|
|
-9.6K
|
$38.35
|
-$368.81K
|
|
SEC
|
Morosini Deborah
|
EVP, Chief of Clinical Affairs
|
|
-100
|
$40.00
|
-$4.00K
|
|
SEC
|
Pierce Christopher
|
EVP and Chief of Business Oper
|
|
-200
|
$40.00
|
-$8.00K
|
|
SEC
|
Scherle Peggy
|
Chief Scientific Officer
|
|
-4.6K
|
$38.34
|
-$177.51K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+10K
|
$12.85
|
+$133.33K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+9.9M
|
$19.00
|
+$188.32M
|
|
SEC
|
Bonita David P
|
N/A
|
|
+9.6M
|
$19.00
|
+$181.82M
|
|
SEC
|
Combs Andrew
|
EVP, Head of Chemistry
|
|
+1K
|
$19.00
|
+$19.00K
|
|
SEC
|
Dier Mardi
|
N/A
|
|
+10K
|
$19.00
|
+$190.00K
|
|
SEC
|
Morosini Deborah
|
EVP, Chief of Clinical Affairs
|
|
+444
|
$19.00
|
+$8.44K
|
|
SEC
|
ORBIMED CAPITAL LLC
|
N/A
|
|
+9.6M
|
$19.00
|
+$181.82M
|
|
SEC
|
Pierce Christopher
|
EVP and Chief of Business Oper
|
|
+3.8K
|
$19.00
|
+$71.25K
|
|